menu
    • menu
    [{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Protein therapeutics","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0.88,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.88,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"Evox Therapeutics \/ Takeda"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"RNA interference","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Evox Therapeutics","amount2":1.23,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":1.23,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Evox Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Exosome-mediated RNAi","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Evox Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Evox Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Exosome-based therapeutics","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Evox Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Evox Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Evox Therapeutics \/ Evox Therapeutics"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Series C Financing","leadProduct":"EVX-101","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Redmile Group","highestDevelopmentStatusID":"4","companyTruncated":"Evox Therapeutics \/ Redmile Group"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Antibody-loaded Exosomes","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Evox Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Antibody-loaded Exosomes","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Evox Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Exosome-encapsulated AAV-based Gene Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Evox Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Icahn School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Evox Therapeutics \/ Icahn School of Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals by Evox Therapeutics

    Menu

    Evox Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exosome-encapsulated AAV-based Gene Therapy

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Discovery

                            Sponsor : Icahn School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evox Therapeutics Enters into Agreement to Advance Next Generation Exosome-Delivered AAV Gene Therapy for the ...

                            Details : The collaboration aims to work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving treatments for heart disease.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 04, 2023

                            Lead Product(s) : Exosome-encapsulated AAV-based Gene Therapy

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Discovery

                            Sponsor : Icahn School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-loaded Exosomes

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Evox Therapeutics Presents Progress Across its Deliverex™Exosome Therapeutics Platform with Nine Presentatio...

                            Details : The nine presentations highlight the progress the Company has made in modulating exosome pharmacokinetics through extension of circulation half-life and improved tissue-targeting via display of ligands on Antibody-loaded Exosomes.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 25, 2022

                            Lead Product(s) : Antibody-loaded Exosomes

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-loaded Exosomes

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            International Society for Cell & Gene Therapy Presentations Illustrate Evox Therapeutics Proprietary Exosome E...

                            Details : Antibody-loaded exosomes, which covered recent advances on engineering exosomes as a display platform for biologics, new in vivo data on antibody-directed targeting of exosomes to tumours, and new data supporting the concept of in situ produced drug-load...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 09, 2022

                            Lead Product(s) : Antibody-loaded Exosomes

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVX-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Redmile Group

                            Deal Size : $95.4 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Evox Therapeutics Completes £69.2 Million Series C Financing

                            Details : Proceeds from this financing will support the advancement of Evox’s exosome-based therapeutics pipeline, including progression of several rare disease assets into the clinic, and continued development of its world-leading DeliverEX exosome drug platfor...

                            Brand Name : EVX-101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 18, 2021

                            Lead Product(s) : EVX-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Redmile Group

                            Deal Size : $95.4 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exosome-based therapeutics

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Discovery

                            Recipient : University of Oxford

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evox Therapeutics Announces Launch of Strategic Collaboration with the University of Oxford

                            Details : The collaboration will run over three years and will capitalise on the world-class exosome research environment in Oxford, leveraging exosome therapeutics expertise and resources from both Evox and the University to drive innovation within rare disease d...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 17, 2020

                            Lead Product(s) : Exosome-based therapeutics

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Discovery

                            Recipient : University of Oxford

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exosome-mediated RNAi

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Evox Therapeutics Expands Existing Exosome Patent Portfolio With Further Grant Covering Exosomes for RNA Thera...

                            Details : The recently issued US patent provides broad coverage for pharmaceutical compositions comprising exosomes containing nucleic acid-based therapeutics, such as RNAi agents and antisense oligonucleotides, which have been loaded by electroporation.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 15, 2020

                            Lead Product(s) : Exosome-mediated RNAi

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA interference

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Eli Lilly

                            Deal Size : $1,230‬.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement Wit...

                            Details : During this research collaboration and five-target license agreement, Evox will be responsible for exosome engineering in order to achieve brain/CNS-targeting, drug loading and analytics and some in vitro and in vivo studies.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $20.0 million

                            June 09, 2020

                            Lead Product(s) : RNA interference

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Eli Lilly

                            Deal Size : $1,230‬.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Evox Therapeutics

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Protein therapeutics

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $882.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration

                            Details : Deal allows Evox to continue advancing its exosome-based targeting and delivery technology, while also leveraging Takeda’s development and clinical expertise to advance these partnered programmes.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $44.0 million

                            March 26, 2020

                            Lead Product(s) : Protein therapeutics

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $882.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth